Wei Chen, Qian Pierre, Tedrow Usha, Mak Raymond, Zei Paul C
Harvard Medical School, Boston, MA, US.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, US.
Arrhythm Electrophysiol Rev. 2020 Feb 12;8(4):285-293. doi: 10.15420/aer.2019.04.
Ventricular tachycardia (VT) is associated with significant morbidity and mortality. Radiofrequency catheter ablation can be effective for the treatment of VT but it carries a high rate of recurrence often attributable to insufficient depth of penetration for reaching critical arrhythmogenic substrates. Stereotactic body radioablation (SBRT) is a commonly used technology developed for the non-invasive treatment of solid tumours. Recent evidence suggests that it can also be effective for the treatment of VT. It is a non-invasive procedure and it has the unique advantage of delivering ablative energy to any desired volume within the body to reach sites that are inaccessible with catheter ablation. This article summarises the pre-clinical studies that have formed the evidence base for SBRT in the heart, describes the clinical approaches for SBRT VT ablation and provides perspective on next steps for this new treatment modality.
室性心动过速（VT）与显著的发病率和死亡率相关。射频导管消融术可有效治疗VT，但复发率高，这通常归因于到达关键致心律失常基质的穿透深度不足。立体定向体部放疗（SBRT）是一种为实体肿瘤非侵入性治疗而开发的常用技术。最近的证据表明，它对VT治疗也有效。这是一种非侵入性手术，具有将消融能量传递到体内任何所需体积以到达导管消融无法触及部位的独特优势。本文总结了为心脏SBRT奠定证据基础的临床前研究，描述了SBRT VT消融的临床方法，并对这种新治疗方式的下一步发展提供了展望。
